Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic Leukemia

Conditions

• Acute Promyelocytic Leukemia (APL)

Interventions

• DRUG: Treatment A: Arsenic Trioxide (ATO) Intravenous
• DRUG: Treatment B: SDK001 (Arsenic Trioxide Oral solution) under faster state
• DRUG: Treatment C: SDK001 (Arsenic Trioxide Oral solution) under fed state
• DRUG: Treatment D: SDK001 (Arsenic Trioxide Oral solution) with calcium carbonate

Sponsor

SDK Therapeutics, Inc.

Collaborators

• [object Object]